NASDAQ:NKTX - Nkarta Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $76.00
  • Forecasted Upside: 343.93 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$17.12
▲ +0.01 (0.06%)

This chart shows the closing price for NKTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Nkarta Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NKTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NKTX

Analyst Price Target is $76.00
▲ +343.93% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Nkarta in the last 3 months. The average price target is $76.00, with a high forecast of $81.00 and a low forecast of $70.00. The average price target represents a 343.93% upside from the last price of $17.12.

This chart shows the closing price for NKTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 contributing investment analysts is to buy stock in Nkarta.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/1/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/30/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/28/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/26/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/25/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/23/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/23/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/10/2021Evercore ISIReiterated RatingBuy$70.00Medium
7/15/2021OppenheimerInitiated CoverageOutperform$75.00Low
6/29/2021Cantor FitzgeraldBoost Price TargetOverweight$71.00 ➝ $78.00High
6/16/2021MizuhoReiterated RatingBuy$81.00High
5/9/2021Evercore ISIReiterated RatingBuy$70.00High
3/17/2021Cantor FitzgeraldReiterated RatingOverweightHigh
12/23/2020MizuhoBoost Price TargetBuy$47.00 ➝ $81.00N/A
12/7/2020MizuhoBoost Price TargetBuy$34.00 ➝ $47.00High
8/4/2020Evercore ISIInitiated CoverageOutperform$55.00High
8/4/2020Stifel NicolausInitiated CoverageBuy$41.00High
8/4/2020MizuhoInitiated CoverageBuy$34.00High
8/4/2020CowenInitiated CoverageOutperformHigh
(Data available from 10/23/2016 forward)

News Sentiment Rating

-0.05 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/27/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/26/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/26/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/25/2021
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/25/2021
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/24/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
9/23/2021
  • 0 very positive mentions
  • 19 positive mentions
  • 3 negative mentions
  • 4 very negative mentions
10/23/2021

Current Sentiment

  • 0 very positive mentions
  • 19 positive mentions
  • 3 negative mentions
  • 4 very negative mentions
Nkarta logo
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was incorporated in 2015 and is based in South San Francisco, California.
Read More

Today's Range

Now: $17.12
Low: $16.05
High: $17.50

50 Day Range

MA: $29.13
Low: $16.94
High: $38.36

52 Week Range

Now: $17.12
Low: $16.05
High: $79.16

Volume

241,026 shs

Average Volume

248,904 shs

Market Capitalization

$563.37 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.03

Frequently Asked Questions

What sell-side analysts currently cover shares of Nkarta?

The following Wall Street research analysts have issued research reports on Nkarta in the last year: Cantor Fitzgerald, Evercore ISI, Mizuho, Oppenheimer Holdings Inc., and Zacks Investment Research.
View the latest analyst ratings for NKTX.

What is the current price target for Nkarta?

4 Wall Street analysts have set twelve-month price targets for Nkarta in the last year. Their average twelve-month price target is $76.00, suggesting a possible upside of 343.9%. Mizuho has the highest price target set, predicting NKTX will reach $81.00 in the next twelve months. Evercore ISI has the lowest price target set, forecasting a price of $70.00 for Nkarta in the next year.
View the latest price targets for NKTX.

What is the current consensus analyst rating for Nkarta?

Nkarta currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe NKTX will outperform the market and that investors should add to their positions of Nkarta.
View the latest ratings for NKTX.

How do I contact Nkarta's investor relations team?

Nkarta's physical mailing address is 6000 SHORELINE COURT SUITE 102, SOUTH SAN FRANCISCO CA, 94080. The official website for Nkarta is www.nkartatx.com.